Relmada Therapeutics Inc (RLMD) 1.3900 $RLMD Relmada

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Relmada Therapeutics Inc (RLMD) 1.3900 $RLMD

Relmada Therapeutics' d-Methadone Receives Orphan Drug Designation for Management of Postherpetic Neuralgia
PR Newswire - Tue Jun 07, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that d-Methadone (dextromethadone, REL-1017), a N-methyl-d-aspartate (NMDA) receptor antagonist in development as a treatment for both depression and chronic neuropathic pain, has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia. Postherpetic neuralgia (PHN) is a painful neuropathic condition resulting from an outbreak of the herpes zoster virus, otherwise known as shingles.

Relmada Therapeutics to Present at the LD Micro Invitational Conference
PR Newswire - Wed Jun 01, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it will present at the LD Micro Invitational Conference on Tuesday, June 7, 2016 at the Luxe Sunset Bel Air Hotel in Los Angeles, CA.

OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.
LTEA: 4.39 (+0.18)

Relmada Therapeutics to Present at the 5th Annual Marcum MicroCap Conference
PR Newswire - Thu May 26, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it will present at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016 in New York City at the Grand Hyatt Hotel.

Relmada Therapeutics Announces Promotion of Michael D. Becker to Chief Financial Officer
PR Newswire - Mon May 16, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced the promotion of Michael D. Becker to chief financial officer, effective as of May 11, 2016.

Relmada Therapeutics Announces Results of In Vivo Study Showing d-Methadone has Antidepressant-like Effects
PR Newswire - Wed May 04, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced the results of an in vivo study showing that administration of d-Methadone (REL-1017), a N-methyl-d-aspartate (NMDA) receptor antagonist, results in antidepressant-like effects. Results are shown to be comparable to those achieved in similar treatment models using ketamine.

Relmada Therapeutics to Present at the Joseph Gunnar "Pioneers 2016" Conference
PR Newswire - Thu Apr 28, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that it will present at the Joseph Gunnar "Pioneers 2016" Conference on May 5, 2016 at the New York Palace Hotel in New York City.

Relmada Therapeutics Provides Additional Details Regarding Upcoming R&D Day
PR Newswire - Tue Apr 26, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that it will hold its first R&D Day on May 4, 2016, from 10:00 a.m. to 12:00 p.m.

Relmada Therapeutics' Michael Becker Interviewed by The Life Sciences Report
Marketwired - Thu Apr 21, 8:02AM CDT
To treat chronic pain without risk of addiction is to straddle a knife's edge. But Relmada Therapeutics Inc. (OTCQB: RLMD) has a small fleet of compounds in development that address both sides of an issue that has become a newsmaker, given the recent upsurge in heroin addiction and the ever-present conundrum of alleviating severe pain in chronic disease and after surgery. In this interview with The Life Sciences Report, Relmada's Michael Becker describes the company's programs, which are advancing steadily toward the marketplace.

Relmada Therapeutics, Inc. Provides Update on Nasdaq Up-Listing Process
PR Newswire - Thu Apr 14, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD) a clinical-stage company developing novel therapies for the treatment of chronic pain, today provided investors with an update regarding the Company's qualification for up-listing to The Nasdaq Capital Market ("Nasdaq". As previously disclosed, the Company submitted an initial listing application with Nasdaq in the second half of 2015. The Company now believes that it satisfies each of the exchange's applicable listing requirements, with the exception of the $4.00 bid price requirement. In accordance with the Nasdaq Listing Rules, the Company's stock price must close at or above $4.00 per share for 30 of the most recent 60 trading days in order for the Company to be eligible to list.

UPDATE -- OTCQX and OTCQB Companies to Present at 2016 Roth Conference
PR Newswire - Mon Mar 14, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the 28th Annual ROTH Conference, taking place March 13-16 at the Ritz-Carlton in Dana Point, CA. The ROTH Conference, hosted by ROTH Capital Partners, LLC, is one of the largest small-cap investment conferences in the U.S., featuring presentations by senior executives from hundreds of public and private companies in a wide variety of sectors.
VRAY: 3.37 (+0.13), DMPI: 6.80 (-0.03), CDXC: 4.00 (-0.39), EKSO: 3.85 (-0.10)

OTCQX And OTCQB Companies To Present At 2016 ROTH Conference
PR Newswire - Thu Mar 10, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the 28th Annual ROTH Conference, taking place March 13-16 at the Ritz-Carlton in Dana Point, CA. The ROTH Conference, hosted by ROTH Capital Partners, LLC, is one of the largest small-cap investment conferences in the U.S., featuring presentations by senior executives from hundreds of public and private companies in a wide variety of sectors.
VRAY: 3.37 (+0.13), DMPI: 6.80 (-0.03), CDXC: 4.00 (-0.39), EKSO: 3.85 (-0.10)

Relmada Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference
PR Newswire - Tue Feb 02, 7:00AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD) a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the Company will present at the 18th Annual BIO CEO & Investor Conference on Monday, February 8th at 3:30 p.m. Eastern Time. The conference will take place at the Waldorf Astoria Hotel in New York City.

Relmada Therapeutics Files Amended Complaint Against Laidlaw and Its Principals, Matthew Eitner and James Ahern
PR Newswire - Tue Jan 26, 6:00AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD) ("Relmada" or the "Company", a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that it has filed a motion to amend its complaint against Laidlaw & Company (UK) Ltd. ("Laidlaw" in the U.S. District Court for the District of Nevada. The motion to file an amended complaint is part of the lawsuit that the Company had previously filed in the Nevada District Court. The amended complaint includes an additional legal claim based on Laidlaw's breach of the fiduciary duty that it owed to Relmada when Laidlaw disclosed confidential information that it acquired in its capacity as the Company's investment banker. Relmada is also seeking monetary damages arising from fees and costs that it incurred responding to Laidlaw's false and misleading proxy materials in December 2015.

Relmada Therapeutics Selected to Present at 2016 Biotech Showcase(TM) in San Francisco
PR Newswire - Mon Jan 11, 7:00AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD) a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the company has been selected to present at the 8th Annual Biotech Showcase(TM) Conference at 2:00 PM Pacific Time (5:00 PM Eastern Time) on Wednesday, January 13, 2016. The presentation will take place in Track C - Mission II at the Parc 55 Hotel in San Francisco.

Relmada Therapeutics Successfully Completes Multiple Ascending Dose Study of d-Methadone for Neuropathic Pain
PR Newswire - Mon Jan 04, 7:00AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD) ("Relmada" or the "Company), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it completed its multiple ascending dose ("MAD" study with d-Methadone (dextromethadone, REL-1017), its novel, N-methyl-D-aspartate ("NMDA" receptor antagonist being developed for the treatment of neuropathic pain. Relmada previously completed a single ascending dose ("SAD" study in March 2015. The design of the Company's Phase II proof-of-concept study in neuropathic pain, anticipated to start in the first half of 2016, will be based on this study's findings.

Relmada Therapeutics Announces Results of Annual Meeting of Stockholders
PR Newswire - Wed Dec 30, 10:55AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD) ("Relmada" or "the Company", a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that, at the Company's 2015 Annual Meeting of Stockholders, Relmada stockholders voted to elect all of Relmada's director nominees: Shreeram Agharkar, PhD, and Maged Shenouda, R. Ph., MBDA. The final tabulation indicates that more than 94% of votes cast at the Annual Meeting were in support of Messrs. Agharkar and Shenouda.

Relmada Therapeutics Recommends Stockholders Vote "FOR" Relmada's Director Nominees on the WHITE Proxy Card Today
PR Newswire - Mon Dec 28, 7:30AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD) ("Relmada" or the "Company", a clinical-stage company developing novel therapies for the treatment of chronic pain, today reiterated its Board's unanimous recommendation that stockholders vote "FOR" the Company's highly qualified, independent director nominees - Shreeram Agharkar, PhD, and Maged Shenouda R. Ph., MBA - on the WHITE proxy card today.

U.S. Federal Court Grants Preliminary Injunction Against Laidlaw & Company and its Principals Matthew Eitner and James Ahern
PR Newswire - Wed Dec 23, 7:30AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD) ("Relmada" or the "Company", a clinical-stage company developing novel therapies for the treatment of chronic pain, announced that following a hearing, the U.S. District Court for the District of Nevada granted Relmada's request and granted a Preliminary Injunction against Laidlaw & Company (UK) Ltd. and its principals, Matthew Eitner and James Ahern. The Court Order enjoins Laidlaw and Messrs. Eitner and Ahern from "continuing to disseminate false and misleading proxy materials."

Corrected Press Release--Shareholder Value Creation Committee Will Continue To Fight For Shareholder Rights
PR Newswire - Mon Dec 21, 2:10PM CST
The Committee of Relmada Shareholders for Value Creation, (the Shareholder Value Creation Committee) issued its press release on December 11, 2015, which press release omitted a sentence regarding the retraction of certain previously issued open letters to shareholders and characterized the temporary restraining order as preventing the solicitation of proxies, the characterization of which is being corrected herein. The corrected press release is as follows:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 385

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 67

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 33

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 77

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Daqo New Energy Faces Key Investor Meeting in December

Updated Category News Views 44

Spotlight on December's Agenda for Daqo Shareholders Who'd have thought we'd be looking at another year end with the same burning energy interests? Daqo New Energy Corp. (NYSE: DQ) is setting up for its annual general meeting (AGM) dated December 10, 2026. Mark your calendars, because these gatherings can be more than just straightforward affairs; sometimes they reveal...

Continue Reading
KuCoin Unveils $1.1M USDT Black Friday Bonanza

Updated Category News Views 0

KuCoin's Festive Fireworks: Black Friday Bonanza Sometimes the crypto world feels like a carnival, and KuCoin's latest act is the $1.1 million USDT prize pool, rolling out as part of its 'Tis The Season holiday campaign. A move that matches the glitz of Tomorrowland Winter experiences, adding more sparkle to the crypto stage. Behind the Scenes of the KuCoin-Tomorrowland...

Continue Reading
ZTE Reinvents Energy for AI Data Centers

Updated Category News Views 25

The Great Race: Power and AI in Sync Here we are, neck-deep in the AI era, where the demand for raw computing power just won’t quit. With every data-hungry application and supercharged algorithm, companies are scrambling to keep up. But there’s a nasty little dragon in this fairy tale—energy efficiency. ZTE isn’t just acknowledging this beast; they’re ready to...

Continue Reading
Net Zero Efforts to Cost Europe €60B Annually by 2050

Updated Category News Views 38

Hefty Prices Loom Over Net Zero Commitments Well, strap in for a wallet buster, folks. Europe's largest players are staring down the barrel of a colossal €60 billion annual bill to clean up their carbon mess by 2050. That's the ticker in Senken's latest report, 'Pace of Change 2026.' Talks like these remind me there's no such thing as a free lunch, especially when...

Continue Reading
Sivers Semiconductors: Strategy Behind 2027 AGM Plans

Updated Category News Views 113

Setting the Stage for a Crucial Year Ah, the dance of corporate governance—an arena where maneuvering is an art. Sivers Semiconductors AB, a name that's becoming synonymous with innovation in the photonics and wireless solutions sector, is prepping for its 2027 Annual General Meeting. Ahead of this pivotal event, they're forming a Nomination Committee to shape future...

Continue Reading

Top 5 Most Recently Viewed Articles

Cypherpunk Technologies Boosts Zcash Holdings Significantly Year-Over-Year

Updated Category News Views 108

Cypherpunk Technologies Expands Zcash Accumulation CAMBRIDGE, Mass. — Cypherpunk Technologies Inc. (Nasdaq: CYPH), a company deeply engaged in privacy technology, has recently accelerated its efforts to accumulate Zcash, significantly boosting its treasury holdings. This move reflects their strategic commitment to enhancing their corporate asset portfolio and addressing...

Continue Reading
Insights from Access LIVE: The Future of Beverage Leadership

Updated Category News Views 253

Insights from Access LIVE: The Future of Beverage Leadership Leaders from the nation's largest distributors convened to share their insights on innovation, growth, and the future of the beverage alcohol industry. The session, known as "Wholesaler Power Hour — Market Drivers: Wholesale Leaders Blazing a Path to Success," took place on the LIVE Stage at Access LIVE 2025,...

Continue Reading
Understanding Microsoft's Competitive Edge in the Software Sector

Updated Category News Views 211

Dynamic Insights into Microsoft and Its Competitors In the rapidly evolving business landscape, a thorough examination of companies is vital for investors and enthusiasts alike. This article delves into a detailed comparative analysis of Microsoft (NASDAQ: MSFT) relative to its main competitors within the software industry. By evaluating essential financial metrics,...

Continue Reading
The Transformative Financial Journey of Pan American Silver Stock

Updated Category News Views 154

The Impact of Long-Term Investment in Pan American Silver Investing in stocks is often seen as a journey, and Pan American Silver (NYSE: PAAS) stands as a shining example of how patience can yield extraordinary rewards over the years. Over the last decade, Pan American Silver has surpassed market performance, boasting an annualized return of 22.95%, which is significantly...

Continue Reading
Linc Housing Initiates Construction of 90 Affordable Units

Updated Category News Views 219

Linc Housing Begins Construction on New Affordable Homes In a promising development for families in need, Linc Housing has commenced the construction of three new affordable apartment communities. This initiative will create 90 new homes specifically designed for low-income individuals and families. The timing could not be more critical, as communities grapple with an...

Continue Reading